Argitalpenak (46) OFELIA BANIANDRÉS RODRÍGUEZ argitalpenak

2024

  1. Dose reduction is a feasible strategy in patients with plaque psoriasis who achieve sustained response with secukinumab: a retrospective, multicenter cohort study in daily practice setting

    International Journal of Dermatology, Vol. 63, Núm. 4, pp. 503-511

  2. Ustekinumab is effective and safe in the long-term treatment of erythrodermic psoriasis: Multicenter study in daily practice

    JEADV Clinical Practice

2023

  1. Effectiveness of secukinumab for the treatment of erythrodermic psoriasis: Multicentre study in daily practice

    Journal of the European Academy of Dermatology and Venereology

  2. High adherence to secukinumab in patients with moderate to severe psoriasis: a long-term multicenter study in a daily practice setting

    International Journal of Dermatology

2022

  1. Design and implementation of a mobile app for the pharmacotherapeutic follow-up of patients diagnosed with immune-mediated inflammatory diseases: eMidCare

    Frontiers in Immunology, Vol. 13

  2. Effectiveness and safety profile of secukinumab for the treatment of patients with generalized pustular psoriasis in daily practice

    Journal of the European Academy of Dermatology and Venereology

  3. Information and Communication Technologies in Patients With Immune-Mediated Inflammatory Diseases: Cross-sectional Survey

    Journal of medical Internet research, Vol. 24, Núm. 9, pp. e37445

  4. Knowledge and role of dermatologists in life-threatening infections: a national survey among hospital skin specialists

    Journal of the European Academy of Dermatology and Venereology

  5. Risankizumab in psoriasis: prior biologics failure does not impact on short-term effectiveness

    Expert Opinion on Biological Therapy

2021

  1. Characterization and Outcomes in Patients Treated With Apremilast in Routine Clinical Practice in Spain: Results From the APPRECIATE Study

    Actas Dermo-Sifiliograficas, Vol. 112, Núm. 9, pp. 817-827

  2. Incidence of severe COVID-19 outcomes in psoriatic patients treated with systemic therapies during the pandemic: A Biobadaderm cohort analysis

    Journal of the American Academy of Dermatology, Vol. 84, Núm. 2, pp. 513-517

  3. Multicenter Retrospective Study of Secukinumab Drug Survival in Psoriasis Patients in a Daily Practice Setting: A Long-Term Experience in Spain

    Dermatology and Therapy, Vol. 11, Núm. 6, pp. 2207-2215

2020

  1. A retrospective, observational multicenter study of 141 patients treated with ustekinumab 90 mg

    Dermatologic Therapy, Vol. 33, Núm. 4

  2. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases

    British Journal of Dermatology, Vol. 183, Núm. 1, pp. 71-77

  3. Long-term safety of nine systemic medications for psoriasis: A cohort study using the Spanish Registry of Adverse Events for Biological Therapy in Dermatological Diseases (BIOBADADERM) Registry

    Journal of the American Academy of Dermatology, Vol. 83, Núm. 1, pp. 139-150

  4. Maculopapular eruptions associated to COVID-19: A subanalysis of the COVID-Piel study

    Dermatologic Therapy, Vol. 33, Núm. 6

  5. The risk of urinary tract infections in patients with psoriasis on systemic medications in Biobadaderm Registry: A prospective cohort study

    Journal of the American Academy of Dermatology, Vol. 82, Núm. 3, pp. 738-741

2019

  1. Women with moderate-to-severe psoriasis in Spain (BIOBADADERM registry) show more than a 50% reduction in age-adjusted fertility rate when compared with the general population

    British Journal of Dermatology

2018

  1. Change over time in the rates of adverse events in patients receiving systemic therapy for psoriasis: A cohort study

    Journal of the American Academy of Dermatology, Vol. 78, Núm. 4, pp. 798-800

  2. New polymorphisms associated with response to anti-TNF drugs in patients with moderate-to-severe plaque psoriasis

    Pharmacogenomics Journal, Vol. 18, Núm. 1, pp. 70-75